T细胞成熟 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
Reverse-phase high-performance liquid chromatography is the standard technique for assessing purity and concentration, because the peptide's hydrophobicity allows clean separation from related impurities. Mass spectrometry confirms molecular identity and detects sequence errors or truncations. Amino acid analysis and peptide mapping supply additional structural confirmation when required. Chromatographic purity values reported on certificates of analysis describe the proportion of the main peak and do not by themselves establish biological activity.
Like most short peptides, thymosin alpha-1 is susceptible to hydrolysis under strongly acidic or basic conditions and to oxidation when exposed to air over long periods. The acetylated amino terminus blocks one common degradation route, which contributes to the molecule's relative robustness in solution. Lyophilized material generally retains potency for extended periods when kept cold and dry. Once reconstituted, aqueous solutions are less stable and are typically used within a defined window rather than held indefinitely at ambient temperature.
Routine handling calls for storage of the lyophilized powder at refrigerated temperatures, away from light, in a sealed container. Working solutions are often prepared in sterile water or buffer and kept cold between uses. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation and loss of material. Laboratories usually record lot number, reconstitution date, and storage conditions so that any change in behavior can be traced to a specific preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
Several factors accelerate degradation: alkaline pH, elevated temperature, exposure to oxidants, and the presence of residual moisture. Deamidation of asparagine residues and oxidation of methionine are the most commonly reported degradation routes. Because the peptide lacks disulfide bonds, it does not undergo the thiol-related aggregation seen in some other biologics, but physical aggregation can still occur at high concentration. Stability data are product-specific, and extrapolating shelf life between formulations is not reliable.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Storage recommendations center on low temperature, dryness, and protection from repeated freezing and thawing. The intact powder is commonly held at 20 degrees below zero Celsius or colder, while a working solution is divided into single-use aliquots to limit freeze-thaw cycles. Buffered saline or phosphate-buffered saline at neutral pH is frequently used as a diluent. Light sensitivity is not well documented, yet amber vials or foil wrapping are common practice for long-term storage of peptide stocks.
Identity and purity are assessed with a small set of standard peptide methods. Reversed-phase high-performance liquid chromatography separates the main peak from truncated or oxidized species, and its area percentage is the usual purity measure. Mass spectrometry confirms the observed molecular mass against the expected value, while amino acid analysis or peptide mapping checks composition and sequence. Specifications for research-grade material are often stated as 95 percent or higher, though the exact limit depends on the supplier and the intended use.
Laboratory supplies of the peptide usually arrive as a lyophilized powder in sealed vials. The powder is hygroscopic, so a vial should be allowed to reach room temperature before it is opened to prevent condensation on the contents. Weighing and transfer are best performed in a low-humidity environment with clean tools. Once dissolved, the solution should be mixed gently rather than vortexed, because foaming and shear can reduce recovery of the peptide.
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
As of May 2021, Pakistan operates six licensed commercial nuclear power plants. The Pakistan Atomic Energy Commission (PAEC) oversees these plants, while the Pakistan Nuclear Regulatory Authority ensures their safe operation. These plants contribute approximately 5.8% to Pakistan's electricity supply, while fossil fuels (crude oil and natural gas) provide 64.2%, hydroelectric power provides 29.9%, and coal contributes 0.1%. The KANUPP-I, Pakistan's first commercial nuclear power plant, was supplied by Canada in 1971. Sino-Pakistani nuclear cooperation began in the 1980s, leading to the establishment of CHASNUPP-I. In 2005, both countries proposed a joint energy security plan, aiming for a generation capacity exceeding 160,000 MWe by 2030. Pakistan's Nuclear Energy Vision 2050 targets a capacity of 40,000 MWe, with 8,900 MWe expected by 2030. In June 2008, the nuclear complex at Chashma in Punjab Province expanded with the installation of Chashma-III and Chashma–IV reactors, each with 325–340 MWe, costing ₨129 billion, with ₨80 billion from international sources, mainly China. Another agreement for China's assistance was signed in October 2008, seen as a response to the US–India agreement. The project's cost was then US$1.7 billion, with a foreign loan of US$1.07 billion. In 2013, Pakistan established a second nuclear complex in Karachi with plans for additional reactors, similar to Chashma. Electrical energy in Pakistan is generated by various corporations and distributed evenly among the four provinces by the National Electric Power Regulatory Authority (NEPRA).
=== Deep sea alkaline vents === Nick Lane believes that no known life forms could have utilized zinc-sulfide based photosynthesis, lightning, volcanic pyrite synthesis, or UV radiation as a source of energy. Rather, he instead suggests that deep sea alkaline vents is more likely to have been a source energy for early cellular life. Serpentinization at alkaline hydrothermal vents produce methane and ammonia. Mineral particles that have similar properties to enzymes at deep sea vents would catalyze organic compounds out of dissolved CO2 within seawater. Porous rock might have promoted condensation reactions of biopolymers and act as a compartment of membranous structures, however it is unknown about how it could promote coding and metabolism. Acetyl phosphate, which is readily synthesized from thioacetate, can promote aggregation of adenosine monophosphate of up to 7 monomers which is considered energetically favored in water due to interactions between nucleobases. Acetyl phosphate can stabilize aggregation of nucleotides in the presence of Na+ and could possibly promote polymerization at mineral surfaces or lower water activity. An external proton gradient within a membrane would have been maintained between the acidic ocean and alkaline seawater. The descendants of the last universal common ancestor, bacteria and archaea, were probably methanogens and acetogens. The earliest microfossils, dated to be 4.28 to 3.77 Ga, were found at hydrothermal vent precipitates. These microfossils suggest that early cellular life began at deep sea hydrothermal vents.
=== 1934 coup d'état === The 1934 coup d'état was executed by the Military Union and the Zveno, who removed Nikola Mushanov from power. It reflected the authoritarian trend in Europe. In this coup, Kimon Georgiev played an important role. At a meeting of the Union's Central Government, held at the house of Kimon Georgiev, it was decided to stage a coup on 19 May. Damyan Velchev and Kimon Georgiev were at the head of the coup.
== Contributions == De made significant contributions to the recent understanding of cholera and related diarrhoeal diseases and set a permanent milestone in the modern view of diseases caused by bacterial exotoxins. Followed by the discovery of Vibrio cholerae in 1884 by Robert Koch, many works have been carried out all over the world to answer many questions related with its pathogenesis and mode of transmission in causing outbreaks. The seminal works of De in Calcutta (now Kolkata) during 1950–60 breached several qualms pertaining to the enteric toxin produced by bacteria including V. cholerae and Escherichia coli. Three of his works viz., ligated intestinal loop method (which was a reinvention of Violle and Crendiropoulo method in 1915, but De was unaware of this work and made an independent discovery) for studying cholera in rabbit model; ileal loop model to demonstrate the association of some strains of E. coli with diarrhoea and lastly but most importantly is his discovery of cholera toxin in 1959 in the cell-free culture filtrate of V. cholerae that stimulated a specific cellular response. As noted by Garfield in his 1986 tribute, De was the first to demonstrate that cholera bacteria secrete enterotoxin. This discovery eventually promoted research to find a treatment aimed directly at neutralising the cholera enterotoxin. De's paper "Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae," while initially unrecognised, today is considered a milestone in the history of cholera research. Biochemist W. E.
==== Structure ==== The myophosphorylase structure consists of 842 amino acids. The molecular weight of the unprocessed precursor is 97 kDa. The three-dimensional structure has been determined for this protein. The interactions of several amino acids in myophosphorylase's structure are known. Ser-14 is modified by phosphorylase kinase during activation of the enzyme. Lys-680 is involved in binding the pyridoxal phosphate, which is the active form of vitamin B6, a cofactor required by myophosphorylase. By similarity, other sites have been estimated: Tyr-76 binds AMP, Cys-109 and Cys-143 are involved in subunit association, and Tyr-156 may be involved in allosteric control.
Sources: en.wikipedia.org
The best-characterized reference (“type”) strain of S. boulardii is CBS 5926, which is also deposited under the culture collection numbers ATCC 74012 and CNCM I-745. This strain dominates commercial use of S. boulardii and is produced by the pharmaceutical company Biocodex; it has been evaluated in more than 90 randomized clinical trials. In addition to CNCM I-745, several manufacturers market S. boulardii supplements derived from distinct, often proprietary strains, including CNCM I-1079, CNCM I-3799, and DBVPG 6763, although it remains unclear whether it is genetically identical to CBS 5926.
Prolonged fasting Diarrheal illness in young children, especially rotavirus gastroenteritis Idiopathic ketotic hypoglycemia Isolated growth hormone deficiency, hypopituitarism Insulin excess Hyperinsulinism due to several congenital disorders of insulin secretion Insulin injected for type 1 diabetes Hyperinsulinism-hyperammonemia syndrome (HIHA) due to glutamate dehydrogenase 1 gene. Can cause intellectual disability and epilepsy in severe cases. Gastric dumping syndrome (after gastrointestinal surgery) Other congenital metabolic diseases; some of the common include Maple syrup urine disease and other organic acidurias Type 1 glycogen storage disease Type III glycogen storage disease. Can cause less severe hypoglycemia than type I Phosphoenolpyruvate carboxykinase deficiency, causes metabolic acidosis and severe hypoglycemia. Disorders of fatty acid oxidation Medium chain acylCoA dehydrogenase deficiency (MCAD) Familial Leucine sensitive hypoglycemia Accidental ingestions including pharmacy misfills Sulfonylureas, propranolol and others Ethanol (mouthwash, alcoholic beverages)
== Mechanism of action == C-terminal CendR motif engages with widely expressed neuropilin-1 receptors to trigger an increased permeability of the vasculature and penetration of tissue parenchyma by an endocytotic/exocytotic transport mechanism. The CendR pathway starts with an endocytosis step that is distinct from known endocytosis pathways. It most closely resembles macropinocytosis, but unlike macropinocytosis, the CendR pathway is receptor (neuropilin)-initiated and its activity is controlled by the nutrient status of the cell or tissue. CendR is an active transport process that requires energy. It is not limited to extravasation, but also includes penetration of tissue parenchyma, potentially via cell-to-cell transport. CendR elements that are not C-terminally exposed are unable to bind to neuropilin-1. However, such cryptic CendR elements can be activated by proteolytic cleavage (e.g. by furin, urokinase type plasminogen activator, and other proteases of suitable substrate specificity).
The field went through multiple cycles of optimism throughout its history, followed by periods of disappointment and loss of funding, known as AI winters. Funding and interest increased substantially after 2012, when graphics processing units (GPUs) started being used to accelerate neural networks, and deep learning outperformed previous AI techniques. This growth accelerated further after 2017 with the transformer architecture. In the 2020s, an AI boom coincided with advances in generative AI, which became widespread and allowed for the creation and modification of media. In addition to AI safety and unintended consequences and harms from the use of AI, ethical concerns, AI's long-term effects, environmental effects, and potential existential risks have prompted discussions of AI regulation.
The 1939 Molotov–Ribbentrop Pact, a non-aggression agreement between Nazi Germany and the Soviet Union, had left the KSČ in disarray. But ever faithful to the Soviet line, the KSČ began a more active struggle against the Germans after Operation Barbarossa, Germany's attack on the Soviet Union in June 1941.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
The lyophilized solid is normally held at 2 to 8 °C in a sealed, light-protected container. Dry storage limits both hydrolysis and microbial growth. Material kept this way remains stable for the shelf life stated by the supplier.